title: Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma.
authors.forename: Kelley V
authors.initials: KV
authors.lastname: Foyil
authors.forename: Dana A
authors.initials: DA
authors.lastname: Kennedy
authors.forename: Laurie E
authors.initials: LE
authors.lastname: Grove
authors.forename: Nancy L
authors.initials: NL
authors.lastname: Bartlett
authors.forename: Amanda F
authors.initials: AF
authors.lastname: Cashen
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D000079963:Brentuximab Vedotin; D002330:Carmustine / Q000008:administration & dosage; D017321:Clinical Trials, Phase I as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage / Q000627:therapeutic use*; D017728:Lymphoma, Large-Cell, Anaplastic / Q000188:drug therapy* / Q000601:surgery; D060046:Maintenance Chemotherapy; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D012074:Remission Induction; D033581:Stem Cell Transplantation; D014182:Transplantation, Autologous; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D018796:Immunoconjugates; D003561:Cytarabine; D014750:Vincristine; D005047:Etoposide; D000079963:Brentuximab Vedotin; D004317:Doxorubicin; D003520:Cyclophosphamide; D008558:Melphalan; D002330:Carmustine; D011241:Prednisone